{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:22:45Z","timestamp":1785151365730,"version":"3.55.0"},"reference-count":117,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice.<\/jats:p>","DOI":"10.3390\/genes10040261","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T03:21:26Z","timestamp":1554175286000},"page":"261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine"],"prefix":"10.3390","volume":"10","author":[{"given":"Cristina Luc\u00eda","family":"D\u00e1vila-Fajardo","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-9902","authenticated-orcid":false,"given":"Xando","family":"D\u00edaz-Villamar\u00edn","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3963-6546","authenticated-orcid":false,"given":"Alba","family":"Ant\u00fanez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Genomics Unit, Centro Pfizer-Universidad de Granada-Junta de Andaluc\u00eda de Gen\u00f3mica e Investigaci\u00f3n Oncol\u00f3gica (Genyo), 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Estefan\u00eda","family":"Fern\u00e1ndez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Garc\u00eda-Navas","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2202-0662","authenticated-orcid":false,"given":"Luis Javier","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Genomics Unit, Centro Pfizer-Universidad de Granada-Junta de Andaluc\u00eda de Gen\u00f3mica e Investigaci\u00f3n Oncol\u00f3gica (Genyo), 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Augusto","family":"D\u00e1vila-Fajardo","sequence":"additional","affiliation":[{"name":"English Department, Official Language School Leganes, 28915 Legan\u00e9s, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Cabeza Barrera","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"Hla-b*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1311388","article-title":"A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon","volume":"369","author":"Verhoef","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A randomized trial of genotype-guided dosing of warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/S0140-6736(14)62219-4","article-title":"Pharmacogenomic testing and response to warfarin","volume":"385","author":"Wu","year":"2015","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","article-title":"Identification of patients with variants in tpmt and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease","volume":"149","author":"Coenen","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.apha.2018.04.003","article-title":"Implementation of pharmacogenomics in everyday clinical settings","volume":"83","author":"Bank","year":"2018","journal-title":"Adv. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2217\/pgs-2018-0097","article-title":"Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations","volume":"19","author":"Luzum","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.602","article-title":"Implementing pharmacogenomics in europe: Design and implementation strategy of the ubiquitous pharmacogenomics consortium","volume":"101","author":"Cecchin","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpt.725","article-title":"Corrigendum: Implementing pharmacogenomics in europe: Design and implementation strategy of the ubiquitous pharmacogenomics consortium","volume":"102","author":"Cecchin","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cpt.762","article-title":"Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group","volume":"103","author":"Bank","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bcp.12319","article-title":"European medicines agency initiatives and perspectives on pharmacogenomics","volume":"77","author":"Ehmann","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"McDonagh","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jacc.2007.10.002","article-title":"2007 focused update of the acc\/aha\/scai 2005 guideline update for percutaneous coronary intervention: A report of the american college of cardiology\/american heart association task force on practice guidelines","volume":"51","author":"King","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kushner, F.G., Hand, M., Smith, S.C., King, S.B., Anderson, J.L., Antman, E.M., Bailey, S.R., Bates, E.R., Blankenship, J.C., and Casey, D.E. (2009). 2009 focused updates: ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC\/AHA\/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2205\u20132241.","DOI":"10.1002\/ccd.22351"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ahj.2007.04.014","article-title":"Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis","volume":"154","author":"Snoep","year":"2007","journal-title":"Am. Heart J."},{"key":"ref_16","first-page":"33","article-title":"Determinants to optimize response to clopidogrel in acute coronary syndrome","volume":"3","author":"Giusti","year":"2010","journal-title":"Pharmgenomics Pers. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in abcb1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the triton-timi 38 trial: A pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jama.2010.1566","article-title":"Clopidogrel and the reduced-function CYP2C19 genetic variant: A limited piece of the overall therapeutic puzzle","volume":"304","author":"Fuster","year":"2010","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2217\/pgs.12.153","article-title":"Current status of clopidogrel pharmacogenomics","volume":"13","author":"Giusti","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.gene.2014.12.051","article-title":"Genetic polymorphisms of CYP2C19*2 and abcb1 c3435t affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome","volume":"558","author":"Wang","year":"2015","journal-title":"Gene"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Su, J., Xu, J., Li, X., Zhang, H., Hu, J., Fang, R., and Chen, X. (2012). Abcb1 c3435t polymorphism and response to clopidogrel treatment in coronary artery disease (cad) patients: A meta-analysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046366"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1538-7836.2010.03921.x","article-title":"Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy","volume":"8","author":"Sibbing","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-st acute coronary syndrome","volume":"7","author":"Frere","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/FPC.0b013e32834ff6e3","article-title":"The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting","volume":"22","author":"Harmsze","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_28","unstructured":"US Department of Health and Human Services (2010). FDA Drug Safety Communication: Reduced Effectiveness of Plavix (Clopidogrel) in Patients Who Are Poor Metabolizers of the Drug."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome p450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/j.1538-7836.2010.03923.x","article-title":"Prasugrel vs. Clopidogrel for cytochrome p450 2c19-genotyped subgroups: Integration of the triton-timi 38 trial data","volume":"8","author":"Sorich","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome p450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and abcb1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the plato trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijcard.2016.09.088","article-title":"Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent","volume":"225","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FJC.0000000000000337","article-title":"Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a chinese population","volume":"67","author":"Shen","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (rapid gene): A prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/tpj.2015.17","article-title":"A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with st-elevation myocardial infarction: The rapid stemi study","volume":"16","author":"So","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.ijcard.2013.06.014","article-title":"Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial","volume":"168","author":"Xie","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: The pharmclo trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16-22.e1","DOI":"10.1016\/j.ahj.2014.03.006","article-title":"CYP2C19 genotype-guided antiplatelet therapy in st-segment elevation myocardial infarction patients-rationale and design of the patient outcome after primary pci (popular) genetics study","volume":"168","author":"Bergmeijer","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/gim.2014.76","article-title":"A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users","volume":"17","author":"Osnabrugge","year":"2015","journal-title":"Genet. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.dib.2016.12.019","article-title":"The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent","volume":"10","author":"Villamarin","year":"2017","journal-title":"Data Brief."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kheiri, B., Osman, M., Abdalla, A., Haykal, T., Pandrangi, P.V., Chahine, A., Ahmed, S., Osman, K., Bachuwa, G., and Hassan, M. (2018). CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Catheter. Cardiovasc. Interv.","DOI":"10.1002\/ccd.27949"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/0300060516677190","article-title":"Genotyping-guided approach versus the conventional approach in selection of oral p2y12 receptor blockers in chinese patients suffering from acute coronary syndrome","volume":"45","author":"Tam","year":"2017","journal-title":"J. Int. Med. Res."},{"key":"ref_48","unstructured":"American College of Cardiology Annual Scientific Session (2018). Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (Adapt), American College of Cardiology Annual Scientific Session (ACC 2018)."},{"key":"ref_49","first-page":"730","article-title":"Can prasugrel decrease the extent of periprocedural myocardial injury during elective percutaneous coronary intervention?","volume":"127","author":"Tomaniak","year":"2017","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical pharmacogenetics implementation consortium guidelines for cytochrome p450-2c19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Scott","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.clpt.6100507","article-title":"Pharmacogenetics: From bench to byte","volume":"83","author":"Swen","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From bench to byte\u2014An update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehs059","article-title":"The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The charisma genetics study","volume":"33","author":"Bhatt","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajmg.c.31390","article-title":"Clinical pharmacogenetics implementation: Approaches, successes, and challenges","volume":"166C","author":"Weitzel","year":"2014","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/clpt.2011.371","article-title":"Operational implementation of prospective genotyping for personalized medicine: The design of the vanderbilt predict project","volume":"92","author":"Pulley","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","article-title":"Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention","volume":"16","author":"Cavallari","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e002069","DOI":"10.1161\/CIRCGEN.117.002069","article-title":"Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Lee","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fragoulakis, V., Bartsakoulia, M., Diaz-Villamarin, X., Chalikiopoulou, K., Kehagia, K., Ramos, J.G.S., Martinez-Gonzalez, L.J., Gkotsi, M., Katrali, E., and Skoufas, E. (2019). Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in spanish patients undergoing percutaneous coronary intervention. Pharmacogenomics J.","DOI":"10.1038\/s41397-019-0069-1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/j.1875-9114.2012.01048","article-title":"Cost-effectiveness of cytochrome p450 2c19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel","volume":"32","author":"Reese","year":"2012","journal-title":"Pharmacotherapy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M13-1999","article-title":"Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome","volume":"160","author":"Kazi","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/pgs-2016-0008","article-title":"Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome","volume":"17","author":"Jiang","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_64","first-page":"552","article-title":"Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention","volume":"21","author":"Johnson","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-016-0397-9","article-title":"A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions","volume":"34","author":"Plumpton","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11239-006-9030-7","article-title":"Genotypes of the cytochrome p450 isoform, cyp2c9, and the vitamin k epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: A prospective study","volume":"22","author":"Carlquist","year":"2006","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical pharmacogenetics implementation consortium guidelines for cyp2c9 and vkorc1 genotypes and warfarin dosing","volume":"90","author":"Johnson","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003088-200847090-00002","article-title":"Pharmacogenetics of oral anticoagulants: A basis for dose individualization","volume":"47","author":"Stehle","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.med.070808.170037","article-title":"Pharmacogenetics of warfarin","volume":"61","author":"Kamali","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin","volume":"84","author":"Gage","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_71","first-page":"99","article-title":"Pharmacogenetics of warfarin: Current status and future challenges","volume":"7","author":"Wadelius","year":"2007","journal-title":"Pharm. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1160\/TH03-06-0379","article-title":"Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin","volume":"91","author":"Gage","year":"2004","journal-title":"Thromb. Haemost."},{"key":"ref_73","unstructured":"(2015). Coumadin- (Warfarin Sodium) Tablet [Package Insert], Bristol-Myers Squibb Pharma Company."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"International Warfarin Pharmacogenetics Consortium, Klein, T.E., Altman, R.B., Eriksson, N., Gage, B.F., Kimmel, S.E., Lee, M.T., Limdi, N.A., Page, D., and Roden, D.M. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360, 753\u2013764.","DOI":"10.1056\/NEJMoa0809329"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/pgs.15.48","article-title":"Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in brazilian patients: Highlighting the importance of population-specific calibration","volume":"16","author":"Santos","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1160\/TH11-12-0848","article-title":"A new algorithm to predict warfarin dose from polymorphisms of cyp4f2, cyp2c9 and vkorc1 and clinical variables: Derivation in han chinese patients with non valvular atrial fibrillation","volume":"107","author":"Wei","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jacc.2010.08.643","article-title":"Genetic warfarin dosing: Tables versus algorithms","volume":"57","author":"Finkelman","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","article-title":"A pharmacogenetic versus a clinical algorithm for warfarin dosing","volume":"369","author":"Kimmel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_79","first-page":"1763","article-title":"Genotype-guided dosing of vitamin k antagonists","volume":"370","author":"Kimmel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/FTD.0000000000000192","article-title":"Clinical practice recommendations on genetic testing of cyp2c9 and vkorc1 variants in warfarin therapy","volume":"37","author":"Shaw","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/br.2016.617","article-title":"Clinical application of a new warfarin-dosing regimen based on the cyp2c9 and vkorc1 genotypes in atrial fibrillation patients","volume":"4","author":"Jiang","year":"2016","journal-title":"Biomed. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jama.2017.11469","article-title":"Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: The gift randomized clinical trial","volume":"318","author":"Gage","year":"2017","journal-title":"JAMA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bcp.12475","article-title":"Genotype-guided drug prescribing: A systematic review and meta-analysis of randomized control trials","volume":"80","author":"Goulding","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11239-014-1099-9","article-title":"Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing","volume":"39","author":"Liao","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijcard.2014.06.031","article-title":"Outcomes of pharmacogenetics-guided dosing of warfarin: A systematic review and meta-analysis","volume":"175","author":"Tang","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1160\/TH15-01-0071","article-title":"Genotype-guided versus standard vitamin k antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis","volume":"114","author":"Hanif","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.thromres.2015.01.018","article-title":"Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: Meta-analysis of randomized controlled trials","volume":"135","author":"Li","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1378\/chest.14-2947","article-title":"Meta-analysis of randomized controlled trials of genotype-guided vs standard dosing of warfarin","volume":"148","author":"Dahal","year":"2015","journal-title":"Chest"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Shi, C., Yan, W., Wang, G., Wang, F., Li, Q., and Lin, N. (2015). Pharmacogenetics-based versus conventional dosing of warfarin: A meta-analysis of randomized controlled trials. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144511"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/14622416.10.2.261","article-title":"Cyp4f2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the italian population","volume":"10","author":"Borgiani","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.amjopharm.2009.07.002","article-title":"Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation","volume":"7","author":"Leey","year":"2009","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/clpt.2013.190","article-title":"Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. Alternative anticoagulation in atrial fibrillation","volume":"95","author":"Pink","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_95","first-page":"88","article-title":"Acenocoumarol: A review of anticoagulant efficacy and safety","volume":"64","author":"Trailokya","year":"2016","journal-title":"J. Assoc. Physicians India"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Verde, Z., Ruiz, J.R., Santiago, C., Valle, B., Bandres, F., Calvo, E., Lucia, A., and Gomez Gallego, F. (2010). A novel, single algorithm approach to predict acenocoumarol dose based on cyp2c9 and vkorc1 allele variants. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011210"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Rathore, S.S., Agarwal, S.K., Pande, S., Singh, S.K., Mittal, T., and Mittal, B. (2012). Therapeutic dosing of acenocoumarol: Proposal of a population specific pharmacogenetic dosing algorithm and its validation in north indians. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037844"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00228-014-1791-x","article-title":"An acenocoumarol dosing algorithm exploiting clinical and genetic factors in south indian (dravidian) population","volume":"71","author":"Shewade","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/eurheartj\/ehr116","article-title":"Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data","volume":"32","author":"Wessels","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Borobia, A.M., Lubomirov, R., Ramirez, E., Lorenzo, A., Campos, A., Munoz-Romo, R., Fernandez-Capitan, C., Frias, J., and Carcas, A.J. (2012). An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in spanish patients with thromboembolic disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041360"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1160\/TH12-08-0631","article-title":"Creating a genotype-based dosing algorithm for acenocoumarol steady dose","volume":"109","author":"Rosafalco","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Tong, H.Y., Davila-Fajardo, C.L., Borobia, A.M., Martinez-Gonzalez, L.J., Lubomirov, R., Perea Leon, L.M., Blanco Banares, M.J., Diaz-Villamarin, X., Fernandez-Capitan, C., and Cabeza Barrera, J. (2016). A new pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed spanish population. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150456"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/jth.13615","article-title":"Dosing algorithms for vitamin k antagonists across vkorc1 and cyp2c9 genotypes","volume":"15","author":"Baranova","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_104","unstructured":"Danese, E., Raimondi, S., Montagnana, M., Tagetti, A., Langaee, T., Borgiani, P., Ciccacci, C., Carcas, A.J., Borobia, A.M., and Tong, H.Y. (2018). The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals. Clin. Pharmacol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2007.06.034","article-title":"Study of the effectiveness of additional reductions in cholesterol and homocysteine (search): Characteristics of a randomized trial among 12064 myocardial infarction survivors","volume":"154","author":"Group","year":"2007","journal-title":"Am. Heart J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for slco1b1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s11095-014-1581-2","article-title":"Development and application of a mechanistic pharmacokinetic model for simvastatin and its active metabolite simvastatin acid using an integrated population pbpk approach","volume":"32","author":"Tsamandouras","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"Slco1b1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"Slco1b1 variants and statin-induced myopathy\u2014A genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The slco1b1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","article-title":"Differential effect of the rs4149056 variant in slco1b1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"ref_113","unstructured":"(2012, February 02). EMA: Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medical Products. Available online: https:\/\/www.ema.europa.eu\/en\/use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.recesp.2011.09.024","article-title":"Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet","volume":"65","author":"Bergmeijer","year":"2012","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMc1402521","article-title":"Genotype-guided dosing of vitamin k antagonists","volume":"370","author":"Koller","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00008571-200401000-00002","article-title":"Effects of CYP2C9 polymorphisms on the pharmacokinetics of r- and s-phenprocoumon in healthy volunteers","volume":"14","author":"Kirchheiner","year":"2004","journal-title":"Pharmacogenetics"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/4\/261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:11Z","timestamp":1760186531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/4\/261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":117,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["genes10040261"],"URL":"https:\/\/doi.org\/10.3390\/genes10040261","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}